NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company’s communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral disease. Ms. Kuhl brings deep expertise in healthcare and pharmaceutical communications, and she has been recognized by industry media for her influence in health ...

Good morning, Frank. Well, that's right. We are inside what's going to be one of the largest biologic drug factories in the US.Now, this right here, this is a bioreactor and this is used to produce monoconal antibodies. Each one holds up to 20,000 lers and just to give you a sense of how big these are. Each tank spans three floors and there will be 16 of them by the time the second phase opens in 2028.And so giving this whole capacity about the ability to produce about 50 million doses of medicine each year ...

Core Insights - Bio Usawa Biotechnology, Ltd. and Sartorius Stedim Biotech have formed a partnership aimed at enhancing Africa's biopharmaceutical industry to address the continent's dual health challenges of infectious and non-communicable diseases [1][2][3] Company Overview - Bio Usawa is a leading biotechnology firm in Rwanda focused on democratizing access to life-saving biopharmaceuticals across Africa, specializing in affordable monoclonal antibodies for cancer, diabetes complications, infectious diseases, and autoimmune conditions [6] - Sartorius Stedim Biotech is a global partner in biopharmaceutical manufacturing, providing innovative solutions to help customers produce biotech medications safely and sustainably, with a reported sales revenue of approximately 2.8 billion euros in 2024 [10] Partnership Objectives - The collaboration will focus on developing and manufacturing affordable, high-quality monoclonal antibodies in Sub-Saharan Africa to combat various health issues, including oncology and diabetes-induced eye diseases [2][3] - Key initiatives include workforce development, process innovation, and technology transfer to empower local talent and infrastructure [4][9] Strategic Pillars - Research & Development: Development of biosimilar cell lines tailored to therapeutic needs in Africa [9] - Workforce Capacity Building: Joint training programs for the African biopharma workforce to ensure long-term sustainability [9] - Technology Enablement: Provision of advanced bioprocessing equipment and consumables for drug manufacturing [9] - Process Optimization: Expertise in ensuring robust, scalable, and cost-effective manufacturing processes [9] - Analytical and Quality Control Support: Strengthening product quality assurance through analytical characterization and quality control testing [9] Industry Impact - This partnership represents a significant step towards building Africa's health sovereignty, aiming to provide equitable access to life-saving innovations and shape the future of healthcare on the continent [5]